Myeloma
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Who can joinAdults
Age18+ years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
6 hospitals in India taking patients for this trial.
HCG Aastha Cancer CentreAhmedabad, GujaratDirections ↗
Marengo Asia Hospitals GurugramGurugram, HaryanaDirections ↗
KLES Dr. Prabhakar Kore Hospital & M.R.CBelagavi, KarnatakaDirections ↗
Mumbai Oncocare Centre - NanachowkMumbai, MaharashtraDirections ↗
Christian Medical College & HospitalLudhianaDirections ↗
Jawaharlal Institute Of Postgraduate Medical Education And ResearchPuducherryDirections ↗
Registry summary (technical)
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Sponsor: Celgene
NCT05519085 on ClinicalTrials.gov
Last updated on the registry 30 Sep 2026 · read by us 20 Oct 2026